Our science
Towards much safer and more effective treatment options in cancer
Antibody-based therapies have revolutionized cancer therapy and have contributed to significantly improved overall survival rates following cancer diagnosis. As the cancer therapy landscape matures further, the future medical need will increasingly shift to effective treatments with superior safety profiles, reducing the severe side effects seen with the current-generation products or avoiding them altogether. At VERAXA, we are building an R&D organization suited to meet this future demand.
A strong history in ADC development
VERAXA has established a strong position in ADC development. Developing safe and efficacious ADCs requires:
- technologies to identify the “right” antibody for the disease context
- the ability to bioengineer the position of payloads
- efficient click chemistry for fast, uniform and stable conjugation of such payloads
VERAXA is the only company with an integrated approach that combines functional antibody screening with bioconjugation technology. We harvest our suite of innovative technologies to develop novel ADCs with a wide therapeutic window and favorable pharmacokinetics. We solve the central challenges of antibody screening and ADC development.
Functional antibody screening
Our droplet-based microfluidics technology allows to harvest the entire immune repertoire to identify internalizing antibodies for ADCs even against challenging targets.
Further applications include the identification of receptor modulating antibodies.
Positional intelligence
Our genetic code expansion technology delivers ultimate precision and flexibility for payload positioning while being minimally invasive and highly efficient.
Bioorthogonal click chemistry
Our highly reactive click group yields uniform ADCs with outstanding stability under bio-compatible conditions while minimizing excess payload.